Keros Therapeutics (KROS) Other Working Capital Changes (2019 - 2025)

Keros Therapeutics has reported Other Working Capital Changes for 7 years, with the latest figure at -$4.2 million in Q4 2025.

• For the quarter ending Q4 2025, Other Working Capital Changes fell 139.07% year-over-year to -$4.2 million; the trailing twelve-month figure through Dec 2025 stood at -$4.0 million (down 139.33% YoY), and the FY2025 full-year result was -$4.0 million, down 139.33% from the prior year.
• Other Working Capital Changes for Q4 2025 stood at -$4.2 million, down from -$770000.0 in the prior quarter.
• The five-year high for Other Working Capital Changes was $10.7 million in Q4 2024, with the low at -$9.3 million in Q4 2023.
• Historically, Other Working Capital Changes has averaged $434263.2 across 5 years, with a median of -$491000.0 in 2024.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes sank 1188.89% — and 2023, when it surged 656.86%.
• Keros Therapeutics' Other Working Capital Changes stood at $46000.0 in 2021, then plunged by 3934.78% to -$1.8 million in 2022, then sank by 429.76% to -$9.3 million in 2023, then soared by 214.31% to $10.7 million in 2024, then slumped by 139.07% to -$4.2 million in 2025.
• The last three Other Working Capital Changes figures came in at -$4.2 million (Q4 2025), -$770000.0 (Q3 2025), and -$2.4 million (Q2 2025), per Business Quant data.